Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

The MET oncogene encodes an unconventional receptor tyrosine kinase with pleiotropic
functions: it initiates and sustains neoplastic transformation when genetically altered …

Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of
cancer. Genetic and biochemical data have demonstrated that the growth and motility factor …

Highlights•Understanding mechanisms of resistance in oncogene-driven lung cancer is
crucial.•MET amplification is a recurrent driver of resistance, across molecularly defined …

Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of
molecular mechanisms including MET gene amplification, mutation, rearrangement, and …

c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth
factor, activates a wide range of different cellular signaling pathways, including those …

The MET tyrosine kinase receptor (also known as the HGF receptor) promotes tissue
remodelling, which underlies developmental morphogenesis, wound repair, organ …

Without epithelial–mesenchymal transitions, in which polarized epithelial cells are converted
into motile cells, multicellular organisms would be incapable of getting past the blastula …

Hepatocellular carcinoma (HCC) is a highly prevalent, treatment-resistant malignancy with a
multifaceted molecular pathogenesis. Current evidence indicates that during …

Hepatocyte growth factor/scatter factor and its receptor, the tyrosine kinase Met, arose late in
evolution and are unique to vertebrates. In spite of this, Met uses molecules such as Gab1 …